Introduction of a second MenB vaccine into Europe - needs and opportunities for public health
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F19%3A00012597" target="_blank" >RIV/75010330:_____/19:00012597 - isvavai.cz</a>
Result on the web
<a href="https://www.tandfonline.com/doi/abs/10.1080/14760584.2019.1578217?journalCode=ierv20" target="_blank" >https://www.tandfonline.com/doi/abs/10.1080/14760584.2019.1578217?journalCode=ierv20</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14760584.2019.1578217" target="_blank" >10.1080/14760584.2019.1578217</a>
Alternative languages
Result language
angličtina
Original language name
Introduction of a second MenB vaccine into Europe - needs and opportunities for public health
Original language description
Introduction: Invasive meningococcal disease (IMD) can be devastating; it is associated with high case fatality rates and long-term sequelae among many survivors. Five serogroups (A, B, C, W, and Y) cause nearly all IMD cases worldwide, and serogroup B (MenB) is the most prevalent in Europe. The European Medicines Agency approved the use of MenB-fHbp (Trumenba (R); Pfizer Ltd, Sandwich, UK) in individuals >= 10 years of age for the prevention of MenB IMD in May 2017. MenB-fHbp contains two lipidated recombinant fHbp variants from two different fHbp subfamilies that help provide broad coverage against circulating meningococcal strains and may also improve antibody response compared to a nonlipidated antigen. Areas covered: This review summarizes the latest epidemiology evaluating the disease burden of MenB in Europe, introduces MenB-fHbp (the vaccine most recently approved in the European Union for the prevention of MenB IMD), and provides an overview of its development. Expert opinion: MenB is by far the most prevalent meningococcal serogroup in Europe, and its epidemiology is not currently addressed by European immunization recommendations. New strategies to prevent MenB IMD in Europe will continue to develop with the growing use of vaccines to prevent MenB disease, with increasing support through national immunization programs.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Review of Vaccines
ISSN
1476-0584
e-ISSN
1744-8395
Volume of the periodical
19
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
15
Pages from-to
225-239
UT code for WoS article
000462339500003
EID of the result in the Scopus database
2-s2.0-85063518503